Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co., Inc. daily Stock Chart
Merck & Co., Inc.
IndexDJIA S&P500 P/E34.04 EPS (ttm)1.83 Insider Own0.04% Shs Outstand2.77B Perf Week1.34%
Market Cap171.86B Forward P/E16.12 EPS next Y3.86 Insider Trans-40.70% Shs Float2.76B Perf Month0.46%
Income5.13B PEG5.43 EPS next Q0.98 Inst Own74.90% Short Float1.09% Perf Quarter13.19%
Sales39.44B P/S4.36 EPS this Y-61.60% Inst Trans0.03% Short Ratio3.09 Perf Half Y18.37%
Book/sh15.66 P/B3.97 EPS next Y2.85% ROA5.20% Target Price- Perf Year29.47%
Cash/sh4.28 P/C14.52 EPS next 5Y6.27% ROE11.60% 52W Range46.54 - 63.53 Perf YTD20.54%
Dividend1.84 P/FCF36.20 EPS past 5Y41.50% ROI6.40% 52W High-2.18% Beta0.69
Dividend %2.96% Quick Ratio1.50 Sales past 5Y-3.00% Gross Margin63.20% 52W Low33.54% ATR0.90
Employees68000 Current Ratio1.90 Sales Q/Q0.60% Oper. Margin18.10% RSI (14)52.35 Volatility1.15% 1.36%
OptionableYes Debt/Eq0.56 EPS Q/Q79.20% Profit Margin13.00% Rel Volume0.71 Prev Close62.96
ShortableYes LT Debt/Eq0.55 EarningsOct 25 BMO Payout99.50% Avg Volume9.71M Price62.15
Recom- SMA20-0.32% SMA501.55% SMA20013.06% Volume6,916,400 Change-1.29%
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Sep-27-16 07:40AM  Major Pharma Continues to See Rising Tide in Short Interest at 24/7 Wall St.
07:00AM  Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy
Sep-26-16 04:03PM  Wall Street Sells Off on Worries Over Clinton-Trump Showdown
02:38PM  Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
11:05AM  A Look at Johnson & Johnsons Recent Stock Performance
Sep-23-16 11:15PM  [$$] Mercks Keytruda Finds Fast Entry Into China Via Medical-Tourism Push at The Wall Street Journal
05:04PM  Youve Heard about the EpiPen Debacle, but Have You Heard This?
01:04PM  Why Analysts Expect Gileads Revenue to Fall in 2016 and 2017
09:11AM  [$$] Merck's Keytruda Finds Fast Entry Into China Via Medical-Tourism Push at The Wall Street Journal
08:08AM  Gilead Sciences Focuses on a Strong Inorganic Growth Strategy
08:00AM  Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25 Business Wire
Sep-22-16 11:59AM  Merck & Co., Inc. Value Analysis (NYSE:MRK) : September 22, 2016
11:04AM  Hows Gilead Sciences Expected to Perform in 2016?
08:04AM  Moves in Cancer Therapeutics among Recent Developments for Ionis
Sep-21-16 11:17AM  BioLineRx Begins Trial on BL-8040/ Keytruda Combination
10:04AM  How Procysbi Fits into Horizons Existing Orphan Drug Portfolio
08:08AM  Merck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : September 21, 2016
Sep-20-16 04:51PM  Stocks pare gains to end flat ahead of Fed, BOJ decisions at MarketWatch
11:04AM  Bristol-Myers Squibbs Role in the Multiple Myeloma Market
10:04AM  How Multiple Research Programs in Lung Cancer Space Are Impacting Bristol-Myers Squibb
08:30AM  Merck to Host Investor Teleconference to Discuss ESMO 2016 Highlights Business Wire
08:04AM  Multiple Segments of Lung Cancer Create Opportunity for Bristol-Myers Squibbs
Sep-19-16 07:26PM  Stocks Trade Lower Monday With Global Central Bank Uncertainty
06:56PM  How To Predict The Next Sarepta (FDA Approval Stock) And Win Big at Forbes
06:50PM  A Breakdown Here In This Sector Would Not Be Healthy
04:04PM  How Valeant Plans to Its Fix Dermatology Portfolio
03:21PM  US stocks mostly higher as banks rise before Fed meeting
10:04AM  And Then Theres MerckAnother Competitor for Roche in Oncology
09:45AM  This Diabetes Breakthrough Is Great News or Terrible News, Depending on Your Perspective at Motley Fool
07:44AM  [$$] Sanofi Files Suit Against Merck at The Wall Street Journal
06:04AM  5 Things You Must Know Before the Market Opens Monday
Sep-18-16 07:25AM  Trump Means Change Equals a Major Inflection Point
Sep-16-16 11:04AM  Doubtful about Roches Bladder Cancer Treatment? Look at Studies
10:04AM  Roche Sees Soaring Revenue from Its Bladder Cancer Treatment
09:19AM  Blog Coverage Teva Expands its Injectables Portfolio and Banks on Merck Cubicin
09:03AM  Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III
08:12AM  Are We Unprepared For Another Ebola Outbreak? at Forbes
08:04AM  Roches Oncology Wheelhouse Stacked with Competitive Drugs
Sep-15-16 08:41AM  Merck and Pfizer's diabetes treatment meets primary endpoint of late-stage trial at MarketWatch
Sep-14-16 08:42AM  Why Pfizer's Stock Is a Big Gamble Right Now at Motley Fool
Sep-13-16 03:28PM  Hillary's Gift to Big Pharma at The Wall Street Journal
01:20PM  Big Pharma Spends Millions to Keep Prices High for California Agencies
12:45PM  New GE, Catepillar & Sinopec Research Reports
09:40AM  Stocks Open Lower; Bonds Flat; Apple Sparks On iPhone Preorders
09:00AM  Merck Publishes 2015/2016 Global Corporate Responsibility Report Business Wire
03:15AM  Merck's Consumer Health Business Presents New Purpose to Help Prepare Society for 100 Healthy Years CNW Group
Sep-12-16 10:13AM  Better Buy: Merck & Co., Inc. vs. Pfizer at Motley Fool
10:04AM  Whats behind Biogen Buyout Rumors?
08:00AM  New Biosimilar can Offer an Effective and Lower Cost Treatment Option for Canadians Living with Rheumatoid Arthritis and Ankylosing Spondylitis PR Newswire
Sep-11-16 07:36AM  Fed Members Should Talk Less, Guide Better and Think Globally
Sep-10-16 12:01AM  [$$] Denmark's Novo Nordisk Plots a Recovery at
Sep-09-16 08:00AM  Merck to Participate at the Morgan Stanley Global Healthcare Conference Business Wire
Sep-08-16 01:23PM  Better Buy: Biogen Inc. vs. Gilead Sciences at Motley Fool
11:29AM  Merck's Lung Cancer Drug Keytruda Under Priority Review
10:04AM  What Are the Possible Threats to Revlimid?
08:30AM  Multi-Billion Dollar Cancer Treatment & Patient Care Industry Boosting Biotech Sector to New Highs CNW Group
08:23AM  This Crushing Blow Sent Bristol-Myers Squibb Co. Down 23% in August at Motley Fool
08:04AM  How Can Revlimid Eventually Lead the Lymphoma Space?
Sep-07-16 06:51PM  Slowing Economic Growth Has Stocks Trading Lower
04:01PM  Wal-Mart, Home Depot Weigh on DJIA Wednesday at 24/7 Wall St.
02:04PM  Gilead Sciences: Open to Opportunities? at
09:21AM  CAR-T Isn't the Only Play in Immunotherapy Stocks at Motley Fool
08:20AM  [$$] FDA to Review Merck Drug as First-Line Treatment for Lung Cancer at The Wall Street Journal
06:45AM  FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Mercks KEYTRUDA┬« (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Business Wire
Sep-05-16 10:04AM  How Are Eli Lillys New Products Performing?
Sep-04-16 12:05PM  Is Biogen a Worthwhile Buyout Candidate? at Motley Fool
Sep-03-16 02:00PM  MRK: How Merck's Stock Price Rose 31.42% in 6 Months at Investopedia
Sep-02-16 08:01AM  [$$] Merck Discontinues Development of Osteoporosis Drug at The Wall Street Journal
07:52AM  Will Merck (MRK) Stock Be Hurt by Discontinuing Osteoporosis Drug Development?
07:00AM  Merck Provides Update on Odanacatib Development Program Business Wire
Sep-01-16 04:35PM  Roche Drug Scores In Lung Cancer, Challenging Bristol-Myers
11:04AM  Why Pfizers Vaccines Business Is Declining
08:06AM  Is Eli Lillys Valuation Higher than Its Peers?
Aug-31-16 06:14PM  Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth
01:47PM  Will Merck (MRK) Stock Be Helped by Bullish Bernstein Note?
12:43PM  Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal
10:05AM  Why Pfizer Is Trading at a Discount on an Earnings Basis
10:05AM  United Therapeutics Makes Novel Technologies a Priority
08:04AM  Franchises that Drove Allergans International Sales in 2Q
Aug-30-16 01:30PM  This Pharma Company Is Leading The Race For A Zika Vaccine
12:19PM  Is Johnson & Johnsons Valuation High Compared to Its Peers?
12:07PM  Merck KGaA -- Moody's changes outlook on Merck KGaA's ratings to stable from negative; affirms ratings at Moody's
Aug-28-16 07:07AM  Time to Shift Your Focus
Aug-27-16 09:44AM  Saturday links: bad intentions
Aug-25-16 11:04AM  AstraZenecas Recent Product Developments
Aug-24-16 04:53PM  Merck Offers Value and Steady Dividend Growth
03:42PM  Health-care sector trails broader market as pricing issues reinflamed at MarketWatch
11:04AM  Performance of AstraZenecas RI&A Segment in 2Q16
11:04AM  How Did Bristol-Myers Squibb Fare in 2Q16?
10:00AM  Write A Prescription For More Pharma M&A With This ETF
Aug-23-16 11:04AM  Whats Challenging Novos Leadership in the US Diabetes Space?
09:50AM  Merck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors
12:09AM  [$$] Pfizers Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
Aug-22-16 01:14PM  Why Did Novos Valuation Multiple Fall Recently?
12:36PM  Monday links: work and drudgery
12:22PM  [$$] Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
09:53AM  Pfizer Will Buy Cancer Drugmaker Medivation For $14 Billion
09:06AM  How Did Bristol-Myers Squibbs Oncology Segment Perform in 2Q16?
Aug-21-16 12:33PM  Curbing Excessive Exuberance May be Premature
Aug-18-16 12:50PM  How Much Medivation Can Really Fetch in a Buyout at 24/7 Wall St.
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM